Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.
In the past week, Gubra announced phase I results regarding a potential anti-obesity medication, several companies announced their first quarter results and some got their price targets updated.
8 of the 20 listed, Danish biotech companies have published news the past week. 13 of the companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date. Fluoguide AB continues to be the best performing stock this year.
Company news the past week
Ascendis Pharma
No news the past week
No news the past week
Cessatech
No news the past week
CS MEDICA A/S’s CANNASEN® Pain Patch receives approval from Israel’s Ministry of Health and is set to debut as the first-ever OTC product with CBD in Israel (Link)
CS Medica published its Q2 2022/2023 report (Link)
No news the past week
Evaxion Biotech
No news the past week
Expres2ion
ExpreS2ion announces financial results for the first quarter 2023 (Link)
Fluoguide
No news the past week
Genmab
EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma (Link)
Updated price targets: JP Morgan cuts its price target to 3200 DKK from 3400 DKK, and H.C. Wainwright raised its price target to $47 from $46 for the ADR shares.
Gubra
Phase 1 trial results from a novel long acting NPY2-receptor agonist in partnership between Gubra A/S and Boehringer Ingelheim presented on European Congress on Obesity (Link)
Initiator Pharma
No news the past week
IO Biotech
No news the past week
Pila Pharma
No news the past week
Saniona
No news the past week
Scandion Oncology
Scandion Oncology will publish its Q1 2023 interim report on Friday May 26
SynAct Pharma
SynAct Pharma Appoints Björn Westberg As CFO (Link)
ViroGates
Sale of shares by majority shareholder in relation to terms for obtaining debt financing from Denmark’s Export and Investment Fund (EIFO) (Link)
ViroGates grants warrants to Denmark’s Export and Investment Fund (EIFO) as the final step in fulfilling the requirements to obtain debt financing (Link)
Zealand Pharma
No news the past week
Y-mAbs Therapeutics
Bank of America raised its price target to $12 from $6
2cureX
No news the past week
SELECTED CASES
SHARE PRICE DEVELOPMENTS
The majority of the Danish Biotech stocks delivered good performance last week. The average return was 1.5%. Saniona rose 30% followed by Initiator Pharma A/S and Evaxion Biotech A/S even though none of the companies presented any news. On the other hand, Pila Pharma A/S and Scandion Oncology A/S and 2Curex AB became the worst performing Danish biotech stocks last week falling 12-13%. In the past year, most of the companies have delivered a negative return. However, there has been two major outliers that have delivered an outstanding share price performance. Saniona AB and Zealand Pharma A/S have risen 193-195%. Both Saniona and Zealand Pharma are working on obesity medicines, and the interest in the stocks is likely to have increased considerably following Novo Nordisk’s major success with Wegovy.
Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment
Overview of share price developments the past week, year-to-date and last twelve months
